Drug intelligence / Profile preview

Deprilium

Development stage
Unknown
Lead developer
NutriMed Group
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Deprilium is a multi-ingredient nutraceutical developed by NutriMed Group, formulated to support mental health and emotional stability. Its primary active components include S-adenosyl-L-methionine (SAMe), levomefolic acid (L-methylfolate), and mecobalamin (Vitamin B12). SAMe serves as a critical methyl donor in the central nervous system, participating in the synthesis of key neurotransmitters such as serotonin, dopamine, and norepinephrine, which regulate mood and cognitive function. Levomefolic acid and mecobalamin act as essential cofactors in the one-carbon metabolism cycle, facilitating the remethylation of homocysteine to methionine and ensuring the continuous availability of SAMe. This combination is intended to address nutritional deficiencies that may contribute to depressive symptoms, anxiety, and emotional instability.

Brand names
Deprilium
Other names
Деприліум
02

Targets

DNMT (DNA methyltransferase)MTR (Methionine synthase)COMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on Deprilium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deprilium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call